Zydus Lifesciences Ltd 2024 AR2
The report highlights Zydus Lifesciences Limited's financial and operational performance for the fiscal year 2023-2024, emphasizing its commitment to innovation and sustainability. The company achieved its highest-ever operating profit and scaled its US formulations business to over US$ 1 billion for the first time. In terms of ESG, the company made significant progress in reducing its carbon footprint, aiming for carbon neutrality in its India operations by FY 2034-35. Additionally, its flagship CSR program at Dahod has provided free medical treatment to 1.9 million patients since 2017.
Company: Zydus Lifesciences Ltd
Sector: Health Care
Country: India
Year: 2024
Type: AR2
Pages: 400
Zydus Lifesciences Ltd
Annual Report
The report highlights Zydus Lifesciences Limited's financial and operational performance for the fiscal year 2023-2024, emphasizing its commitment to innovation and sustainability. The company achieved its highest-ever operating profit and scaled its US formulations business to over US$ 1 billion for the first time. In terms of ESG, the company made significant progress in reducing its carbon footprint, aiming for carbon neutrality in its India operations by FY 2034-35. Additionally, its flagship CSR program at Dahod has provided free medical treatment to 1.9 million patients since 2017.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees